Results 131 to 140 of about 30,694 (295)

Marketing features of derived intoxicating cannabinoid product brands on Instagram: A content analysis

Addiction, EarlyView.
Abstract Background and aims Use of derived intoxicating cannabinoid products (DICPs) has grown in the United States (US), as have associated poisonings, emergency department visits and psychotic episodes. Brand marketing on social media, a largely underregulated marketing channel, may be contributing to this growth.
Kathryn La Capria, Siyan Meng, Alisa A. Padon, Kayla K. Tillett, Scott I. Donaldson, Jon‐Patrick Allem, Matthew E. Rossheim, Cassidy LoParco, Carla J. Berg, Kristina M. Jackson, Julia Chen‐Sankey   +10 more
wiley   +1 more source

Potentiation of catecholamine inhibition of ganglionic transmission by Δ9-tetrahydrocannabinol

, 1977
The effect of Δ9-tetrahydrocannabinol upon exogenous catecholamine inhibition of synaptic transmission was evaluated in the rabbit superior cervical ganglion. Δ9-Tetrahydrocannabinol (7.5 and 15 μg/kg, i.v.) was without effect upon electrically evoked
Goldstein, Frederick J., Strahlendorf, H. K., Vernot, E.   +2 more
core   +1 more source

Methylenedioxymethamphetamine (MDMA)‐related fatal poisoning in Australia, 2016 to 2025: Trends, characteristics and toxicology

Addiction, EarlyView.
Abstract Aims To determine: (1) Population rates of fatal methylenedioxymethamphetamine (MDMA)‐related poisoning over the period 2016–2023, years with high closure rates in the National Coronial Information System (NDIS); (2) the case characteristics of known cases of fatal MDMA‐related poisoning, 2016–2025; and (3) whether there have been changes in ...
Shane Darke, Johan Duflou, Agata Chrzanowska, Michael Farrell, Julia Lappin, Amy Peacock   +5 more
wiley   +1 more source

Clinical applications of wearable devices for individuals with at‐risk substance use and substance use disorders: A systematic review

The American Journal on Addictions, EarlyView.
Abstract Background and Objectives Managing substance use disorders (SUDs) is limited by the lack of longitudinal clinical data during active use and recovery. Wearable devices may help address this gap by capturing physiological and behavioral data in real‐world settings.
Alexandra Sas, Matthew E. Sloan, Yaoyi Xing, Ethan Kim, Dhvani Mehta, Anna Mouzenian, Lena C. Quilty, Jeffrey D. Wardell, Shannon Lange, Daniel Felsky, Victor M. Tang   +10 more
wiley   +1 more source

Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study

, 2001
The intravenous administration of synthetic cannabinoid agonists was recently shown to dose dependently increase acetylcholine release from the rat prefrontal cortex and hippocampus (Eur. J. Pharmacol. 401 (2000) 179].
GOLDBERG SR, DI CHIARA, GAETANO, ACQUAS, ELIO MARIA GIOACHINO, MARROCU P, PISANU, AUGUSTA   +4 more
core   +1 more source

Proof‐of‐concept trial of PP‐01 for mitigating cannabis withdrawal syndrome in participants with cannabis use disorder

The American Journal on Addictions, EarlyView.
Abstract Background and Objectives Cannabis withdrawal symptoms can be severe and protracted, significantly impeding the ability to abstain from cannabis use, resulting in failed quit attempts and relapse. This clinical trial evaluated safety and efficacy of PP‐01, a novel dual‑mechanism of action, investigational agent, for mitigating cannabis ...
Ashley F. Slagle, Jay Constantine, Harvey Kushner, Shelli Graham, Ginger Constantine   +4 more
wiley   +1 more source

Cannabis tolerance reduces symptom relief

Frontiers in Pharmacology
ObjectivesWe measure for the first time how tolerance from repeated consumption of medical cannabis affects acute symptom management.MethodsUsing the Releaf App, medical cannabis patients recorded their symptoms, product type, cannabis consumption method,
Sarah S. Stith, Xiaoxue Li, Franco Brockelman, Keenan Keeling, Branden Hall, Jacob M. Vigil   +5 more
doaj   +1 more source

Toxicokinetic modelling of the synthetic cannabinoid 5F‐MDMB‐P7AICA and its main metabolite in pigs following pulmonary administration

British Journal of Clinical Pharmacology, EarlyView.
Aims Since their emergence on the drug market, synthetic cannabinoids (SC) are still gaining increasing importance in forensic toxicology. The representatives of the so‐called new psychoactive substances have in common that they have not undergone preclinical safety studies. Hence, knowledge on toxicokinetic (TK) data is sparse.
Adrian A. Doerr, Christiane Dings, Omar Zaher, Frederike Nordmeier, Nadja Walle, Matthias W. Laschke, Michael D. Menger, Peter H. Schmidt, Markus R. Meyer, Thorsten Lehr, Nadine Schaefer   +10 more
wiley   +1 more source

Cannabinoids in Chronic Pain Management: A Review of the History, Efficacy, Applications, and Risks

Biomedicines
Background/Objectives: Chronic pain remains a pervasive and challenging public health issue, often resistant to conventional treatments such as opioids, which carry substantial risks of dependency and adverse effects.
Brooks W. Johnson, Natalie H. Strand, John C. Raynak, Christian Jara, Kisanet Habtegiorgis, Brennan A. Hand, Sang Hong, Jillian A. Maloney   +7 more
doaj   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source